Skip to main content

Table 4 Patient characteristics associated with meeting the TM and the CAM

From: Clinical action measures improve the reliability of feedback on quality of care in diabetes centres: a retrospective cohort study

Diabetes type

T1

T2

Meeting the measure

TM–CAM−

TM–CAM +

TM + CAM +

TM–CAM−

TM-CAM +

TM + CAM +

A.

LDL cholesterol

 n

196

30

342

347

62

696

 Age (years), mean

48

51

51 *

69

71

69

 Diabetes duration (years), mean

20

20

22

17

17

18

 Time before start insulin therapy (years), mean

0.2

0.3

0.5

7.8

8.2

8.6

 Duration insulin therapy (years), mean

20

20

21

9.2

8.4

9.2

 Smoking status (%)

  Never smoked

63.7

50.0

65.8

65.6

59.3

66.9

  Ex-smoker

13.5

23.3

12.7

25.0

28.8

24.2

  Smoker

22.8

26.7

21.5

9.4

11.9

8.9

 Presence of complication (%)

  CV_hist1 (° for T2D)

8.7

10.0

4.1

40.9

38.7

15.5

  CV_hist2 (° for T1D, ° for T2D)

13.8

16.7

4.4

48.4

50.0

18.7

  CV_hist3 ($ for T1D, ° for T2D)

15.4

18.5

6.2

52.4

55.2

24.2

  Microvascular complication

51.6

60.9

53.8

71.7

81.8

73.2

  Absent foot pulses or abnormal sensitivity

14.2

16.0

16.0

36.3

43.1

33.5

 Treated with (%)

  Antiplatelet drugs (* for T1D)

29.1

50.0

36.9

71.6

69.4

74.5

  Lipid-lowering drugs ($ for T1D, $ for T2D)

32.6

93.3

50.9

71.5

93.5

83.5

  Antihypertensive drugs

40.8

46.7

51.0

86.4

87.1

87.0

  Oral antidiabetic drugs (° for T2D)

7.7

13.3

8.9

51.3

33.9

58.4

B.

non-HDL cholesterol

 n

315

49

870

713

125

1349

 Age (years), mean

47

49

50 $

69

70

70

 Diabetes duration (years), mean

19

21

22 $

17

17

18

 Time before start insulin therapy (years), mean

0.2

0.4

0.3

7.9

7.5

8.0

 Duration insulin therapy (years), mean

18

21

22 °

8.9

8.7

9.5

 Smoking status (%)

  Never smoked

57.2

61.7

65.0

60.5

60.4

65.0

  Ex-smoker

15.1

19.1

14.9

27.8

29.7

25.2

  Smoker

27.6

19.1

20.0

11.7

9.9

9.8

 Presence of complication (%)

  CV_hist1 (° for T1D, ° for T2D)

9.5

8.2

4.0

37.5

40.3

17.4

  CV_hist2 (° for T1D, ° for T2D)

12.4

10.2

5.3

45.7

55.2

21.1

  CV_hist3 ($ for T1D, ° for T2D)

13.9

14.6

7.8

50.1

60.3

27.0

  Microvascular complication (* for T2D)

52.1

73.0

53.8

74.7

85.3

73.9

  Absent foot pulses or abnormal sensitivity (* for T2D)

12.0

15.4

14.8

37.0

43.3

32.4

 Treated with (%)

  Antiplatelet drugs ($ for T1D)

22.2

36.7

33.0

72.1

69.6

72.4

  Lipid-lowering drugs (° for T1D, ° for T2D)

29.5

98.0

45.2

69.1

95.2

81.9

  Antihypertensive drugs ($ for T1D)

35.9

44.9

45.8

84.9

83.9

86.2

  Oral antidiabetic drugs ($ for T2D)

8.0

8.2

8.4

53.7

41.9

56.4

  1. Patient characteristics that were associated with meeting the TM and the CAM based on LDL cholesterol (Table 4a) and non-HDL cholesterol (Table 4b). Mean age, diabetes duration, time before start insulin therapy and duration of insulin therapy is compared between the population neither meeting the TM nor the CAM (TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between means was tested with the Pairwise Wilcox test, Holm adjustment: p < 0.001(°), p < 0.01 ($) and p < 0.05 (*) vs. not meeting the TM or the CAM (TM-CAM-). The proportion of patients with a complication, treated with drugs, and the distribution of smoking status is compared between the population neither meeting the TM nor the CAM (TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between percentages was tested with the χ2-test: p < 0.001 (°), p < 0.01 ($) and p < 0.05 (*)
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us